Prognostic role of tumor-associated macrophages and angiogenesis in classical Hodgkin lymphoma

References

• Mani H, Jaffe ES. Hodgkin lymphoma: an update on its biology with newer insights into classification. Clin Lymphoma Myeloma 2009;9:206–216.
   PubMedGoogle Scholar
• Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478–1484.
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998;339:1506–1514.
   PubMed Web of Science ®Google Scholar
• Tubiana M, Henry-Amar H, Carde P, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC lymphoma group controlled clinical trials: 1964–1987. Blood 1989;73:47–56.
   PubMed Web of Science ®Google Scholar
• Sup SJ, Alemañy CA, Pohlman B, et al. Expression of bcl-2 in classic Hodgkin's lymphoma: an independent predictor of poor outcome. J Clin Oncol 2005;23:3773–3779.
   PubMed Web of Science ®Google Scholar
• Doussis-Anagnostopoulou IA, Vassilakopoulos TP, Thymara I, et al. Topoisomerase IIα expression as an independent prognostic factor in Hodgkin's lymphoma. Clin Cancer Res 2008;14:1759–1766.
   PubMed Web of Science ®Google Scholar
• Diepstra A, van Imhoff GW, Karim-Kos HE, et al. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J Clin Oncol 2007;25:3101–3108.
   PubMed Web of Science ®Google Scholar
• Hsi ED, Sup SJ, Alemany C, et al. MAL is expressed in a subset of Hodgkin lymphoma and identifies a population of patients with poor prognosis. Am J Clin Pathol 2006;125:776–782.
   PubMed Web of Science ®Google Scholar
• Devilard E, Bertucci F, Trempat P, et al. Gene expression profiling defines molecular subtypes of classic Hodgkin's disease. Oncogene 2002;21:3095–3102.
   PubMed Web of Science ®Google Scholar
• Sanchez-Aguilera A, Montalban C, de la Cueva P, et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 2006;108:662–668.
   PubMed Web of Science ®Google Scholar
• Chetaille B, Bertucci F, Finetti P, et al. Molecular profiling of classic Hodgkin lymphoma tissue uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 2009;113:2765–2775.
   PubMed Web of Science ®Google Scholar
• Alvaro T, Lejeune M, Salvado MT, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005;11:1467–1473.
   PubMed Web of Science ®Google Scholar
• Kelley TW, Pohlman B, Elson P, et al. The ratio of FOXP3 + regulatory T cells to Granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol 2007:128:958–965.
   PubMed Web of Science ®Google Scholar
• Molin D, Edstrom A, Glimelius I, et al. Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. Br J Haematol 2002;119:122–124.
   PubMed Web of Science ®Google Scholar
• Murdoch C, Giannoudis A, Lewis CE. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004;104:2224–2234.
   PubMed Web of Science ®Google Scholar
• Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010:362: 875–885.
   PubMed Web of Science ®Google Scholar
• Tzankov A, Matter MS, Dirnhofer S. Refined prognostic role of CD68-positive tumor macrophages in the context of the cellular micromilieu of classical Hodgkin lymphoma. Pathobiology 2010;77:301–308.
   PubMed Web of Science ®Google Scholar
• Kamper P, Bendix K, Hamilton-Dutoit S, et al. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica 2011;96:269–276.
   PubMed Web of Science ®Google Scholar
• Jakovic LR, Mihaljevic BS, Perunicic Jovanovic MD, et al. The prognostic relevance of tumor associated macrophages in advanced stage classical Hodgkin lymphoma. Leuk Lymphoma 2011;52: 1913–1919.
   PubMed Web of Science ®Google Scholar
• Zaki MAA, Wada N, Ikeda J, et al. Prognostic implication of types of tumor associated macrophages in Hodgkin lymphoma. Virchows Arch 2011;459:361–366.
   PubMed Web of Science ®Google Scholar
• Yoon DH, Koh YW, Kang HJ, et al. CD68 and CD163 as prognostic factors for Korean patients with Hodgkin lymphoma. Eur J Haematol 2011;88:292–305.
   PubMed Web of Science ®Google Scholar
• Deau B, Bachy E, Ribrag V, et al. Macrophage, mast cell and T lymphocyte infiltrations are independent predictive biomarkers of primary refractoriness or early relapse in classical Hodgkin lymphoma. Leuk Lymphoma 2013;54:41–45.
   PubMed Web of Science ®Google Scholar
• Tan KL, Scott DW, Hong F, et al. Tumor associated macrophages predict inferior outcomes in classical Hodgkin lymphoma: a correlative study form the E2496 Intergroup trial. Blood 2012;120:3280–3287.
   PubMed Web of Science ®Google Scholar
• Azambuja D, Natkunam Y, Biasoli I, et al. Lack of association of tumor associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. Ann Oncol 2012;23:736–742.
   PubMed Web of Science ®Google Scholar
• Agostinelli C, Gallamini A, Rigacci L, et al. The prognostic value of biologic markers in classical Hodgkin lymphoma (CHL) patients. Ann Oncol 2012;22(Suppl. 4): Abstract 206.
   Google Scholar
• Harris JA, Jain S, Ren Q, et al. CD163 versus CD68 in tumor associated macrophages of classical Hodgkin lymphoma. Diagn Pathol 2012;7:12–17.
   PubMed Web of Science ®Google Scholar
• Sanchez-Espiridion B, Martin-Moreno AM, Montalban C, et al. Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma. Haematologica 2012;97:1080–1084.
   PubMed Web of Science ®Google Scholar
• Ruan J, Hyjek E, Kermani P, et al. Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphoma. Clin Cancer Res 2006;12:5622–5631.
   PubMed Web of Science ®Google Scholar
• Gratzinger D, Zhao S, Marinelli RJ, et al. Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large cell lymphoma subtypes. Am J Pathol 2007;170: 1362–1369.
   PubMed Web of Science ®Google Scholar
• Ruan J, Hajjar K, Rafii S, et al. Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma. Ann Oncol 2009;20:413–424.
   PubMed Web of Science ®Google Scholar
• Korkolopoulou P, Thymara I, Kavantzas N, et al. Angiogenesis in Hodgkin's lymphoma: a morphometric approach in 286 patients with prognostic implications. Leukemia 2005;19:894–900.
   PubMed Web of Science ®Google Scholar
• Glimelius I, Edstrom A, Fischer M, et al. Angiogenesis and mast cells in Hodgkin lymphoma. Leukemia 2005;19:2360–2362.
   PubMed Web of Science ®Google Scholar
• Grimshaw MMJ, Balkwill FR. Inhibition of monocyte and macrophage chemotaxis by hypoxia and inflammation – a potential mechanism. Eur J Immunol 2001;31:480–489.
   PubMed Web of Science ®Google Scholar
• Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006;66:605–612.
   PubMed Web of Science ®Google Scholar
• Ree HJ, Marshall EK. Macrophage-histiocytes in Hodgkin's disease. The relation of peanut-agglutinin-binding macrophage-histiocytes to clinicopathologic presentation and course of disease. Cancer 1985;56:333–338.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Schioppa T, Porta C, et al. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2006:25:315–322.
   PubMed Web of Science ®Google Scholar
• Igreja C, Courinha M, Cachaço AS, et al. Characterization and clinical relevance of circulating and biopsy derived endothelial progenitor cells in lymphoma patients. Haematologica 2009;92: 469–477.
   Web of Science ®Google Scholar